Prof. Wenxing Qin 秦文星
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment and clinical research for breast cancer and other malignant tumors, including chemotherapy, targeted therapy, endocrine therapy, and immunotherapy.
Dr. Qin holds a doctorate in oncology and completed a postdoctoral fellowship in clinical pharmacy. As a chief physician, Dr. Qin specializes in comprehensive diagnosis and treatment of breast cancer, including chemotherapy, targeted therapy, endocrine therapy, and immunotherapy.
Professional roles
- Member, Chinese Medical Association
- Vice Chair, Youth Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Member, Tumor Oncology Special Committee, National Health Commission Capacity Building and Continuing Education
- Member, Breast Cancer Expert Committee, Chinese Society of Clinical Oncology (CSCO)
Name order: in Chinese the family name comes first (Qin Wenxing). Papers usually list the name as Wenxing Qin or Qin W.
Selected publications
12 papers on PubMed matched by name and affiliation; 4 as first or senior author since 2016. Most recent first- or senior-author papers:
- Mol Cancer, 2025 (first author): ZNF526 drives tumor growth by enhancing SHMT1-dependent serine metabolism and antioxidant capability in TNBC. PubMed 41267037
- J Exp Med, 2025 (first author): PCK1 inhibits cGAS-STING activation by consumption of GTP to promote tumor immune evasion. PubMed 40048154
- Mol Cancer, 2024 (first author): Multiomics-based molecular subtyping based on the commensal microbiome predicts molecular characteristics and the therapeutic response in breast cancer. PubMed 38730464
- MedComm (2020), 2023 (senior author): Modeling cross-talk of RNA modification enzymes reveals tumor microenvironment-associated clinical significance and immunotherapy prediction in hepatobiliary malignancy. PubMed 37090117
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion